Key facts
- Huaaotai Biopharma’s last known valuation is $440.1M (Dec 2024).
- It has raised $27.5M; the latest was Later Stage VC ($27.5M) in Dec 2024.
- Notable investors include Zhejiang Collaboration Investment Management.
- Status: Privately Held (backing).
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Huaaotai Biopharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Huaaotai Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Huaaotai Biopharma
Developer of biologic drug research platforms designed for innovative antibody-based therapies. The company focuses on monoclonal antibodies, bispecific antibodies, fusion proteins, and ADC drug development, providing a GMP-compliant manufacturing system for biologic drug production.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2013
- Website
- huaota.com/
- Ownership
- Privately Held (backing)
Huaaotai Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Huaaotai Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Huaaotai Biopharma in its N-PORT filings yet. We sweep new filings monthly.